newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma to Present Data from Multiple Trials, Including Three Rapid Oral Presentations, at ASCO 2026

  • Ascentage Pharma Group International announced that six abstracts from its clinical studies have been selected for presentation at the 2026 ASCO Annual Meeting held May 29–June 2 in Chicago & online.
  • The selection includes three rapid oral presentations & three poster presentations highlighting the portfolio of Olverembatinib (HQP1351), Lisaftoclax (APG-2575), & Alrizomadlin (APG-115).
  • Dr. Yifan Zhai noted this marks the company's ninth consecutive year presenting at ASCO & emphasized global recognition of their clinical value.
  • Rapid oral presentations will cover Olverembatinib combined with blinatumomab for CML-LBP or Ph+ BCP-ALL; updated Olverembatinib safety/efficacy for CP-CML; & Alrizomadlin alone or with Lisaftoclax for pediatric rhabdomyosarcoma/soft-tissue sarcomas.
  • Poster presentations will detail Olverembatinib results in SDH-deficient tumors; the ongoing POLARIS-2 phase 3 trial for CML; & the ongoing GLORA phase 3 trial for CLL/SLL.
  • Olverembatinib is the first third-generation BCR-ABL inhibitor approved in China, while Lisaftoclax is the first China-developed Bcl-2 selective inhibitor approved there.
  • All three drug candidates remain under investigation & have not yet received FDA approval in the US.
  • Ascentage Pharma is conducting multiple global registrational phase 3 trials including POLARIS-1, POLARIS-2, POLARIS-3, GLORA, GLORA-2, GLORA-3, & GLORA-4.
  • The company maintains global partnerships with major pharmaceutical firms such as Takeda, AstraZeneca, Merck, Pfizer, & Innovent.